M
MBX Biosciences, Inc. (MBX)
NMS – Real Time Price. Currency in USD
36.98
-3.10 (-7.73%)
At close: May 12, 2026, 4:00 PM EDT
38.15
+1.17 (3.16%)
After-hours: May 12, 2026, 7:28 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
36.98
-3.10 (-7.73%)
At close: May 12, 2026, 4:00 PM EDT
38.15
+1.17 (3.16%)
After-hours: May 12, 2026, 7:28 PM EDT
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
| Name | Position |
|---|---|
| Dr. Andreas Moraitis M.D. | Senior Vice President of Clinical Development |
| Dr. Chatan Charan Ph.D. | Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls |
| Dr. Michael A. Dorato DABT, Ph.D. | Sr. Vice President of Discovery & Non-Clinical Development |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer |
| Mr. John W. Smither CPA | Interim Chief Financial Officer |
| Mr. Mark Hope | Senior Vice President of Regulatory & Quality |
| Mr. Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications |
| Mr. Peter Kent Hawryluk MBA | CEO, President & Director |
| Mr. Steven L. Hoerter | Executive Chairperson |
| Ms. Michelle Graham | Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | DEFA14A | mbx_proxy_supplement_202.htm |
| 2026-05-07 | 8-K | mbx-20260507.htm |
| 2026-04-22 | DEFA14A | defa_14a_2026.htm |
| 2026-04-22 | DEF 14A | mbx-20260421.htm |
| 2026-03-12 | S-3ASR | mbx-20260312.htm |
| 2026-03-12 | 8-K | mbx-20260312.htm |
| 2026-03-09 | 8-K | mbx-20260309.htm |
| 2026-02-27 | 8-K | mbx-20260224.htm |
| 2026-02-05 | 8-K | mbx-20260204.htm |
| 2026-01-22 | 8-K | mbx-20260120.htm |